Amgen Switzerland AG
Amgen Switzerland AG is a Biotech company based in Risch-Rotkreuz (Zug) recorded by Swissmedic as the authorisation holder for 28 human medicines. That places it 63 of 334 authorisation holders in Switzerland. Its portfolio is concentrated in Biotechnologika.
Key facts
| Sector | Biotech |
|---|---|
| City | Risch-Rotkreuz |
| Canton | Zug |
| Authorisation holder | Yes |
| Medicines | 28 |
| Founded | Not available |
| Employees | 201-1000 |
| Parent group | Amgen Inc. |
| Activity | Not available |
| Website | amgen.ch |
Medicines authorised in Switzerland
Amgen Switzerland AG is recorded by Swissmedic as the authorisation holder for 28 human medicines. The table shows 28 of them with product code and dispensing category.
Portfolio by product code
Portfolio by dispensing category
28 of 28 authorisations
| Name | Authorisation number | Dispensing category | ATC | First authorised |
|---|---|---|---|---|
| Amgevita 40 mg/0.8 ml | 66979 | B | L04AB04 | 2019-09-13 |
| Amgevita 40 mg/0.8 ml | 67204 | B | L04AB04 | 2019-09-13 |
| Aranesp 10 Mikrogramm | 55725 | A | B03XA02 | 2002-09-13 |
| Blincyto 38.5 mcg | 65654 | A | L01FX07 | 2016-02-25 |
| Imdylltra 1 mg | 69132 | A | L01FX33 | 2026-05-08 |
| Imlygic 10e6 | 65812 | A | L01XL02 | 2016-07-13 |
| Kanjinti 150 mg | 67205 | A | L01FD01 | 2019-11-11 |
| Kyprolis 60 mg | 65690 | A | L01XG02 | 2015-11-23 |
| MVASI 100 mg/4 ml | 67283 | A | L01FG01 | 2019-12-09 |
| Neulasta | 56326 | A | L03AA13 | 2003-09-01 |
| Neupogen Amgen 30 | 51035 | A | L03AA02 | 1991-10-11 |
| Nplate | 61541 | A | B02BX04 | 2011-03-29 |
| Nplate 125 mcg | 69065 | A | B02BX04 | 2023-06-06 |
| Otezla 30mg | 65346 | B | L04AA32 | 2015-07-21 |
| Parsabiv 2.5 mg | 66338 | B | H05BX04 | 2017-09-27 |
| Pavblu 40 mg/ml | 69763 | B | S01LA05 | 2025-06-17 |
| Pavblu 40 mg/ml | 69832 | B | S01LA05 | 2025-06-17 |
| Prolia | 60210 | B | M05BX04 | 2010-08-03 |
| Repatha 140 mg / ml | 65622 | B | C10AX13 | 2016-02-05 |
| Tepezza 500 mg | 69795 | A | L04AG13 | 2025-04-30 |
| Uplizna 100 mg/10ml | 69322 | A | L04AA47 | 2024-03-04 |
| Vectibix 100 mg/5 ml | 57872 | A | L01FE02 | 2008-10-14 |
| Wezenla 130 mg/26 ml | 70187 | B | L04AC05 | 2025-07-23 |
| Wezenla 45 mg / 0.5 ml | 70619 | B | L04AC05 | 2026-08-14 |
| Wezenla 45 mg/0.5 ml | 70188 | B | L04AC05 | 2025-07-23 |
| Wezenla 45 mg/0.5 ml | 70189 | B | L04AC05 | 2025-07-23 |
| XGEVA 120 mg | 61865 | A | M05BX04 | 2011-12-02 |
| XGEVA 120 mg/1 ml | 69520 | A | M05BX04 | 2024-09-18 |
Frequently asked questions
How many medicines does Amgen Switzerland AG have authorised in Switzerland?
Amgen Switzerland AG is recorded by Swissmedic as the authorisation holder for 28 human medicines (as of 1 September 2026). Different strengths under one authorisation number are not counted separately.
Where is Amgen Switzerland AG based?
The Swiss location recorded for Amgen Switzerland AG is Risch-Rotkreuz, Zug.
Is Amgen Switzerland AG a Swissmedic authorisation holder?
Yes. Amgen Switzerland AG appears in the official Swissmedic list of authorised medicinal products as an authorisation holder. Under the Therapeutic Products Act (TPA) the holder is responsible for the quality, safety and product information of its medicines in Switzerland.